Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from alarge cohort of patients with long follow-up.

Abstract

Lenalidomide and dexamethasone (RD) is a standard treatment in relapsed/refractory immunoglobulin light chain (AL) amyloidosis (RRAL). We retrospectively investigated toxicity, efficacy and prognostic markers in 260 patients with RRAL. Patients received a median of two prior treatment lines (68% had been bortezomib-refractory; 33% had received high-dose melphalan). The median treatment duration was four cycles. The 3-month haematological response rate was 31% [very good haematological response (VGHR) in 18%]. The median follow-up was 56·5months and the median overall survival (OS) and haematological event-free survival (haemEFS) were 32 and 9months. The 2-year dialysis rate was 15%. VGHR resulted in better OS (62 vs. 26months, P<0·001). Cardiac progression predicted worse survival (22 vs. 40months, P=0·027), although N-terminal prohormone of brain natriuretic peptide (NT-proBNP) increase was frequently observed. Multivariable analysis identified these prognostic factors: NT-proBNP for OS [hazard ratio (HR) 1·71; P<0·001]; gain 1q21 for haemEFS (HR 1·68, P=0·014), with a trend for OS (HR 1·47, P=0·084); difference between involved and uninvolved free light chains (dFLC) and light chain isotype for OS (HR 2·22, P<0·001; HR 1·62, P=0·016) and haemEFS (HR 1·88, P<0·001; HR 1·59, P=0·008). Estimated glomerular filtration rate (HR 0·71, P=0·004) and 24-h proteinuria (HR 1·10, P=0·004) were prognostic for renal survival. In conclusion, clonal and organ biomarkers at baseline identify patients with favourable outcome, while VGHR and cardiac progression define prognosis during RD treatment.